- Home
- PFGC vs RPRX Comparison
PFGC vs RPRX Comparison
Compare PFGC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFGC
- RPRX
- Stock Information
- Founded
- PFGC 1885
- RPRX 1996
- Country
- PFGC United States
- RPRX United States
- Employees
- PFGC N/A
- RPRX N/A
- Industry
- PFGC Food Distributors
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PFGC Consumer Discretionary
- RPRX Health Care
- Exchange
- PFGC Nasdaq
- RPRX Nasdaq
- Market Cap
- PFGC 16.6B
- RPRX 15.6B
- IPO Year
- PFGC 2015
- RPRX 2020
- Fundamental
- Price
- PFGC $108.75
- RPRX $35.64
- Analyst Decision
- PFGC Strong Buy
- RPRX Strong Buy
- Analyst Count
- PFGC 10
- RPRX 3
- Target Price
- PFGC $110.90
- RPRX $45.33
- AVG Volume (30 Days)
- PFGC 1.5M
- RPRX 4.1M
- Earning Date
- PFGC 11-05-2025
- RPRX 11-05-2025
- Dividend Yield
- PFGC N/A
- RPRX 2.47%
- EPS Growth
- PFGC N/A
- RPRX 54.86
- EPS
- PFGC 2.18
- RPRX 2.32
- Revenue
- PFGC $59,898,900,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- PFGC $14.68
- RPRX $35.01
- Revenue Next Year
- PFGC $6.12
- RPRX $3.14
- P/E Ratio
- PFGC $49.92
- RPRX $15.33
- Revenue Growth
- PFGC 9.54
- RPRX 3.02
- 52 Week Low
- PFGC $68.40
- RPRX $24.05
- 52 Week High
- PFGC $109.05
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- PFGC 68.09
- RPRX 45.51
- Support Level
- PFGC $103.98
- RPRX $34.84
- Resistance Level
- PFGC $106.93
- RPRX $36.94
- Average True Range (ATR)
- PFGC 1.96
- RPRX 0.84
- MACD
- PFGC 0.12
- RPRX -0.09
- Stochastic Oscillator
- PFGC 96.55
- RPRX 48.79
About PFGC Performance Food Group Company
Performance Food Group Co , markets and distributes national and company-branded food and food-related products. The company also specializes in distributing candy, snacks, beverages, cigarettes, other tobacco products, health and beauty care products and other items to vending distributors, box retailers, theaters, convenience stores, drug stores, grocery stores, travel providers, and hospitality providers. The company has three reportable segments: Foodservice, Vistar, and Convenience.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.